Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1
Authors:
- Christian MeiselCMChristian Meisel
- Bengisu AkbilBABengisu Akbil
- Tim MeyerTMTim Meyer
- Erwin LankesELErwin Lankes
- Victor M. CormanVCVictor M. Corman
- Olga StaudacherOSOlga Staudacher
- Nadine UnterwalderNUNadine Unterwalder
- Uwe KölschUKUwe Kölsch
- Christian DrostenCDChristian Drosten
- Marcus A. MallMMMarcus A. Mall
- Tilmann KallinichTKTilmann Kallinich
- Dirk SchnabelDSDirk Schnabel
- 15 July 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (14)
Abstract
Autoantibodies against IFN-α and IFN-ω (type I IFNs) were recently reported as causative for severe COVID-19 in the general population. Autoantibodies against IFN-α and IFN-ω are present in almost all patients with autoimmune polyendocrine syndrome type 1 (APS-1) caused by biallelic deleterious or heterozygous dominant mutations in AIRE. We therefore hypothesized that autoantibodies against type I IFNs also predispose patients with APS-1 to severe COVID-19. We prospectively studied 6 patients with APS-1 between April 1, 2020 and April 1, 2021. Biobanked pre–COVID-19 sera of APS-1 subjects were tested for neutralizing autoantibodies against IFN-α and IFN-ω. The ability of the patients’ sera to block recombinant human IFN-α and IFN-ω was assessed by assays quantifying phosphorylation of signal transducer and activator of transcription 1 (STAT1) as well as infection-based IFN-neutralization assays. We describe 4 patients with APS-1 and preexisting high titers of neutralizing autoantibodies against IFN-α and IFN-ω who contracted SARS-CoV-2, yet developed only mild symptoms of COVID-19. None of the patients developed dyspnea, oxygen requirement, or high temperature. All infected patients with APS-1 were females and younger than 26 years of age. Clinical penetrance of neutralizing autoantibodies against type I IFNs for severe COVID-19 is not complete.Keywords
Funding Information
- German Federal Ministry for Education and Research (82DZL0098B1)
- German Federal Ministry for Education and Research (01IK20337)
- Innovationsfond of Labor Berlin (NA)
- Berlin Institute of Health (NA)
- Deutsche Forschungsgemeinschaft (DFG) Collaborative Research Centre CRC900 “Microbial Persistence and its Control” (project number 158989968,project C8)
This publication has 21 references indexed in Scilit:
- Thymic Epithelial Cells Contribute to Thymopoiesis and T Cell DevelopmentFrontiers in Immunology, 2020
- Severe GABA A receptor encephalitis without seizures: A paediatric case successfully treated with early immunomodulationEuropean Journal of Paediatric Neurology, 2018
- Twenty Years of AIREFrontiers in Immunology, 2018
- Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophyJCI Insight, 2016
- Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune DiseasesImmunity, 2015
- Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type IJournal of Experimental Medicine, 2010
- Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1PLOS Medicine, 2006
- An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domainsNature Genetics, 1997
- Positional cloning of the APECED geneNature Genetics, 1997
- Clinical Variation of Autoimmune Polyendocrinopathy–Candidiasis–Ectodermal Dystrophy (APECED) in a Series of 68 PatientsNew England Journal of Medicine, 1990